Efficacy of infliximab dose escalation in patients with refractory immunotherapy-related colitis: A case series Review

   


Authors: Harris, J. P.; Postow, M. A.; Faleck, D. M.
Review Title: Efficacy of infliximab dose escalation in patients with refractory immunotherapy-related colitis: A case series
Abstract: Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases. © The Author(s) 2022. Published by Oxford University Press.
Keywords: treatment outcome; retrospective studies; retrospective study; immunotherapy; colitis; ulcerative colitis; adverse event; gastrointestinal agents; infliximab; colitis, ulcerative; gastrointestinal agent; humans; human
Journal Title: The Oncologist
Volume: 27
Issue: 4
ISSN: 1083-7159
Publisher: Oxford University Press  
Date Published: 2022-04-01
Start Page: e350
End Page: e352
Language: English
DOI: 10.1093/oncolo/oyac019
PUBMED: 35380715
PROVIDER: scopus
PMCID: PMC8982418
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128160662&doi=10.1093%2foncolo%2foyac019&partnerID=40&md5=739f1f9e143d15e4e040fcdd294e1730
Notes: Article -- Export Date: 2 May 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    361 Postow
  2. David M. Faleck
    51 Faleck
  3. Jessica Harris
    4 Harris
Related MSK Work